Circulating miRNAs have been considered as attractive biomarkers reflecting an underlying pathophysiology in various diseases. MiRNAs can be incorporated into microparticles and are released from the cells when the complex fuses with the plasma membrane, and thus can be observed in the circulating blood. MiRNAs are reportedly involved in the pathophysiological processes of atrial remodeling and therefore become novel therapeutic targets. MicroRNAs (miRNAs) are small (20–25 bp), single-stranded, non-coding RNAs, which post-transcriptionally regulate the gene/protein expression. Although the progression of AF can be assessed by laboratory tests, imaging examinations, and electrophysiological findings, reliable clinical biomarkers have yet to be identified. Catheter ablation is recognized as a standard treatment of AF but its efficacy has been limited in patients who develop atrial remodeling progression, resulting in a rather high rate of AF recurrence. ĪF evolves from a paroxysmal to a persistent form with the progression of atrial remodeling. The increasing prevalence turns this complex arrhythmia into a major health problem. There was no additional external funding received for this study.Ĭompeting interests: The authors have declared that no competing interests exist.Ītrial fibrillation (AF) is the most common sustained arrhythmia, associated with increased morbidity and mortality. All of the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: All relevant data are within the paper and its Supporting Information files.įunding: This work was supported in part by a grant from the Suzuken Memorial Foundation and the Japan Society for the Promotion of Science and the Nitto Foundation. Received: AugAccepted: MaPublished: April 4, 2023Ĭopyright: © 2023 Harada et al. PLoS ONE 18(4):Įditor: Tomohiko Ai, Ohio State University, UNITED STATES (2023) Circulating miR-20b-5p and miR-330-3p are novel biomarkers for progression of atrial fibrillation: Intracardiac/extracardiac plasma sample analysis by small RNA sequencing. Citation: Harada M, Okuzaki D, Yamauchi A, Ishikawa S, Nomura Y, Nishimura A, et al.
0 kommentar(er)
